ad

Dr Lal PathLabs Share Price: 13.4% CAGR in 3 Years as the Delhi-Based Diagnostics Chain Compares With Metropolis Healthcare, Apollo Hospitals and Max Healthcare

19 Nov 2026 • 3:08 pm

Dr Lal PathLabs Share Price: 13.4% CAGR in 3 Years as the Delhi-Based Diagnostics Chain Compares With Metropolis Healthcare, Apollo Hospitals and Max Healthcare

Dr Lal PathLabs Share Price: 13.4% CAGR in 3 Years as the Delhi-Based Diagnostics Chain Compares With Metropolis Healthcare, Apollo Hospitals and Max Healthcare

Dr Lal PathLabs previous close Rs 1,965.40. 3-year CAGR 13.4%. Up 1.5x since 17 Nov 2023. ROE 21.32%. Market cap Rs 32,976 crore.

Quick Answer

The Dr Lal PathLabs share price closed at Rs 1,965.40 on 18 November 2026, a compounded annual return of 13.4% over three years. That compares with Metropolis Healthcare at 11.8%, Apollo Hospitals at 17.2% and Max Healthcare at 18.9%. The company has a market cap of Rs 32,976 crore and a P/E of 56.08 against an industry P/E of 63.96.

The Dr Lal PathLabs share price closed at Rs 1,965.40 on 18 November 2026 and has compounded at 13.4% a year over three years. Dr Lal PathLabs, based in Delhi, runs a network of diagnostic labs and collection centres that offer blood tests, imaging and health packages.

This article places that return beside Metropolis Healthcare, Apollo Hospitals and Max Healthcare. We calculate the three-year CAGR for all four and set the results next to market cap, valuation, return on equity and debt, using prices adjusted for corporate actions.

Click Here – Get Free Investment Predictions

How Much Has the Dr Lal PathLabs Share Price Returned in 3 Years?

The Dr Lal PathLabs stock closed at Rs 1,349.38 on 17 November 2023 and at Rs 1,965.40 on 18 November 2026. Rs 1 lakh invested three years ago would have grown to about Rs 1.46 lakh, which is a CAGR of 13.4%. This is a price return and leaves out dividends.

CAGR condenses a bumpy three-year ride into one yearly number, which is why it is the fairest way to compare companies of different sizes. A stock such as Dr Lal PathLabs can look spectacular on a chart and still have earned a modest yearly return, so the compounded figure keeps the comparison honest.

Diagnostics companies earn steady volumes because tests are repeat and referral driven. The Dr Lal PathLabs share price reflects that pattern, with returns built on test volume growth and a strong balance sheet.

Dr Lal PathLabs vs Metropolis Healthcare, Apollo Hospitals and Max Healthcare: 3-Year CAGR Compared

The table ranks the companies by three-year CAGR. Prices on 17 November 2023 are adjusted for splits and bonuses, and the latest figures are the previous close on 18 November 2026.

Company Close on 17 Nov 2023 Previous close (18 Nov 2026) Price multiple 3-year CAGR
Max Healthcare Rs 607.75 Rs 1,022.85 1.7x 18.9%
Apollo Hospitals Rs 5,478.95 Rs 8,821.00 1.6x 17.2%
Dr Lal PathLabs Rs 1,349.38 Rs 1,965.40 1.5x 13.4%
Metropolis Healthcare Rs 404.35 Rs 564.30 1.4x 11.8%

The Dr Lal PathLabs stock ranks third of the four at 13.4%. It sits ahead of Metropolis Healthcare (11.8%). The companies ahead are Max Healthcare (18.9%) and Apollo Hospitals (17.2%). By market cap the company ranks third of the four at Rs 32,976 crore. Apollo Hospitals is the largest of the four by market cap, while Dr Lal PathLabs is a pure diagnostics business.

Look at the Dr Lal PathLabs share price alongside the peers as a snapshot of the last three years. It describes what happened, and valuation and earnings will decide what happens next.

Valuation and Quality Compared

Company Market cap P/E Industry P/E ROE Debt to equity
Apollo Hospitals Rs 1,26,689 crore 54.20 63.96 21.14% 0.77
Max Healthcare Rs 99,474 crore 72.07 63.96 12.18% 0.33
Dr Lal PathLabs Rs 32,976 crore 56.08 63.96 21.32% 0.09
Metropolis Healthcare Rs 11,704 crore 51.93 63.96 13.66% 0.16

By market cap, Apollo Hospitals is the largest of the group at Rs 1,26,689 crore, while the Dr Lal PathLabs stock stands at Rs 32,976 crore, about 26% of that size. On earnings, Dr Lal PathLabs shares trade at a P/E of 56.08 against an industry P/E of 63.96, a discount of about 12% to the sector, which leaves room if earnings keep growing. Peer multiples are Metropolis Healthcare at 51.93, Apollo Hospitals at 54.20 and Max Healthcare at 72.07.

Return on equity is 21.32% for the Dr Lal PathLabs stock, which ranks first among the four, and debt to equity stands at 0.09. Trailing EPS is Rs 35.03. Dr Lal PathLabs trades at a P/E of 56.08 against an industry P/E of 63.96, with a price to book of 12.02. The ROE of 21.32% is the highest in the group.

What Is Driving the Dr Lal PathLabs Stock?

Dr Lal PathLabs earns revenue from routine and specialised tests, wellness packages and home collection. A large lab network and a wide collection reach help it add test volumes with limited extra spending.

The company earns an ROE of 21.32% and carries a debt to equity of just 0.09, which is the lowest in the group. Its P/E of 56.08 sits below the industry P/E of 63.96.

Investors who follow the Dr Lal PathLabs share price usually track growth in test volumes, revenue per patient, the share of wellness packages and operating margin.

How the Established Players Stack Up

Metropolis Healthcare is a Mumbai-based diagnostics chain with labs and collection centres across India. It compounded at 11.8% a year, on a market cap of Rs 11,704 crore and an ROE of 13.66%.

Apollo Hospitals is a Chennai-based hospital chain with a pharmacy and digital health arm. It compounded at 17.2% a year, on a market cap of Rs 1,26,689 crore and an ROE of 21.14%.

Max Healthcare is a hospital chain with multi-speciality hospitals across several Indian cities. It compounded at 18.9% a year, on a market cap of Rs 99,474 crore and an ROE of 12.18%.

What Should Investors Track Next?

Three things are worth watching on the Dr Lal PathLabs share price. First, growth in test volumes in the next quarterly result. Second, the share of wellness and specialised tests. Third, operating margin as new labs open.

At a P/E of 56.08 the stock trades below the industry P/E of 63.96, which leaves room if volumes keep growing. Competition from other lab chains can affect pricing, so follow each result closely.

Check the Univest Screener for live fundamentals of diagnostics stocks

How to Compare Diagnostics Stocks Yourself

You can repeat this exercise for any pair of stocks, including the Dr Lal PathLabs stock against its peers. Note the adjusted closing price on the base date, take the latest close, divide one by the other, raise the result to the power of one third and subtract one. Then place the CAGR next to market cap, P/E against the industry P/E, ROE and debt to equity. Benchmark the result against the Nifty 50 as well, so you know whether the stock beat the broader market.

A stock that scores well on growth but weakly on quality, or the reverse, deserves closer study before it enters a portfolio. When tracking the Dr Lal PathLabs share price, the same four checks give a more complete picture than price alone.

Download the Univest iOS App or Univest Android App to track the Dr Lal PathLabs share price and compare diagnostics stocks live.

A Diagnostics Chain Beside One Peer and Two Hospital Chains

The Dr Lal PathLabs share price compounded at 13.4% a year over three years, against 11.8% for Metropolis, 17.2% for Apollo Hospitals and 18.9% for Max Healthcare. Its ROE of 21.32% and debt to equity of 0.09 add to the quality case.

Max Healthcare brings the fastest return, Dr Lal PathLabs brings the highest ROE and Metropolis Healthcare brings the lowest P/E. Dr Lal PathLabs offers a light balance sheet and a pure diagnostics focus.

Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).

Frequently Asked Questions

What is the Dr Lal PathLabs share price today?

Ans. Dr Lal PathLabs closed at Rs 1,965.40 on 18 November 2026, according to NSE data. It has a market cap of Rs 32,976 crore and a P/E of 56.08. Check live quotes before acting, as prices change every trading day.

What is the 3-year CAGR of the Dr Lal PathLabs stock?

Ans. Dr Lal PathLabs delivered a price CAGR of 13.4% over three years, moving from Rs 1,349.38 on 17 November 2023 to Rs 1,965.40 on 18 November 2026. The figure excludes dividends and uses adjusted closing prices.

Is Dr Lal PathLabs better than Metropolis?

Ans. Dr Lal PathLabs delivered the higher three-year CAGR at 13.4% against 11.8% for Metropolis. Dr Lal PathLabs has the larger market cap at Rs 32,976 crore against Rs 11,704 crore for Metropolis. Dr Lal PathLabs earns the higher ROE at 21.32% against 13.66%. Metropolis trades at the lower P/E of 51.93 against 56.08. The better choice depends on whether you weigh recent return, size, profitability or valuation most.

What does Dr Lal PathLabs do?

Ans. Dr Lal PathLabs Limited is a Delhi-based diagnostics company that runs laboratories, collection centres and home sample collection services across India.

Is the Dr Lal PathLabs stock debt free?

Ans. The debt to equity ratio of the Dr Lal PathLabs stock is 0.09 and its return on equity is 21.32%. Always check the latest balance sheet for current figures, as debt levels change with expansion plans.

Is Dr Lal PathLabs expensive compared with the industry?

Ans. Dr Lal PathLabs trades at a P/E of 56.08 against an industry P/E of 63.96. A higher multiple reflects expectations of faster growth, which the company must deliver through earnings.

Which diagnostics stock gave the highest return in 3 years?

Ans. Among the companies compared here, Max Healthcare delivered the highest three-year CAGR at 18.9%, followed by Apollo Hospitals at 17.2%. Past returns do not guarantee future performance.

How do I calculate CAGR for a stock?

Ans. Divide the latest price by the starting price, raise the result to the power of one divided by the number of years, and subtract one. Multiply by 100 for a percentage. Use split and bonus adjusted prices for accurate results.

Recent Articles

Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.

Reviews

user-review-1
user-review-2
user-review-3
user-review-4
user-review-5

RESEARCH ANALYST

Get SEBI Registered
advice on the stocks
trending today.

Get 3 FREE Trade Ideas

+91
for Startups Accelerator 2024

for Startups Accelerator 2024

Trusted by 1Cr Indians

Trusted by 1Cr Indians

Awarded No.1 by Economic Times

Awarded No.1 by Economic Times

GET THE APP

Join 1Cr users today.

SEBI Registered Analyst-backed Picks. Free Demat. One App

  • Free Demat account in under 5 minutes
  • Live market data — Nifty, Sensex, sector insights
  • SEBI Registered analyst-backed stock picks
Get it on Google PlayDownload on the App Store
Stocks:
All|a|b|c|d|e|f|g|h|i|j|k|l|m|n|o|p|q|r|s|t|u|v|w|x|y|z

Copyright 2026 Univest. All rights reserved.
Designed with ❤️ in India

arrow down